Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Abeona Therapeutics Inc.

NASDAQ: ABEO · Life Sciences · 9 alerts · CIK 318306

Share price
$2.60Close, Nov 16
Market cap
$149M
Shares outstanding
57.15MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Abeona Therapeutics Inc. filings on SEC EDGAR ↗

6:31 AM ET 8-K
M&A Deal

Abeona Therapeutics Signs $20M M&A Deal with Ellodi Pharmaceuticals, L.P.

Abeona Therapeutics acquired substantially all assets related to APT-1011 (now ABO-801), a Phase 3-ready candidate for eosinophilic esophagitis, from Ellodi Pharmaceuticals. The deal was structured with $20 million in upfront equity consideration (4,494,383 shares) and no upfront cash, with Ellodi eligible for $30 million upon FDA approval and up to $30 million in sales milestones plus royalties.

Value
$20M
Counterparty
Ellodi Pharmaceuticals, L.P.

“The acquisition of ABO-801 is an important step in building Abeona into a diversified commercial-stage company with multiple opportunities for value inflection, adding an asset with substantial revenue potential in a rapidly growing disease.”

Vish Seshadri, Ph.D., Chief Executive Officer of Abeona Therapeutics

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.